Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7337)
All Articles published online
|
Publishing Process of This Article
|
Jun 27, 2019 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541 [PMID: 31293721 DOI: 10.4254/wjh.v11.i6.531] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v11/i6/531.htm |
| Number | Citing Articles |
| 1 |
Yuval Ishay, Yotam Kolben, Asa Kessler, Yaron Ilan. Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathy. American Journal of Physiology-Gastrointestinal and Liver Physiology 2021; 321(4): G400 doi: 10.1152/ajpgi.00186.2021
|
| 2 |
Yasunari Hiramine, Hirofumi Uto, Seiichi Mawatari, Shuji Kanmura, Yasushi Imamura, Takuya Hiwaki, Akiko Saishoji, Atsuko Kakihara, Shigeho Maenohara, Koichi Tokushige, Akio Ido. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatology Research 2021; 51(4): 445 doi: 10.1111/hepr.13622
|
| 3 |
Takemi Akahane, Hitoshi Yoshiji. Role of serum albumin in hepatic encephalopathy. Hepatology Research 2021; 51(4): 353 doi: 10.1111/hepr.13632
|
| 4 |
Deirdre A Collins, Yuan Wu, Kazuhiro Tateda, Hee-Jung Kim, Richard J Vickers, Thomas V Riley. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
. Journal of Antimicrobial Chemotherapy 2021; 76(4): 967 doi: 10.1093/jac/dkaa522
|
| 5 |
Ji Ye Hyun, Seul Ki Kim, Sang Jun Yoon, Su Been Lee, Jin-Ju Jeong, Haripriya Gupta, Satya Priya Sharma, Ki Kwong Oh, Sung-Min Won, Goo Hyun Kwon, Min Gi Cha, Dong Joon Kim, Raja Ganesan, Ki Tae Suk. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease. International Journal of Molecular Sciences 2022; 23(15): 8749 doi: 10.3390/ijms23158749
|
| 6 |
Yuka Hayakawa, Nobuharu Tamaki, Hiroyuki Nakanishi, Masayuki Kurosaki, Yuki Tanaka, Kento Inada, Shun Ishido, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Shun Kaneko, Yutaka Yasui, Yuka Takahashi, Kaoru Tsuchiya, Ryuichi Okamoto, Namiki Izumi. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy. Internal Medicine 2023; 62(7): 973 doi: 10.2169/internalmedicine.0212-22
|
| 7 |
Takuya Iwamoto, Isao Sakaida. Current Status of Rifaximin Treatment for Hepatic Encephalopathy at Our Hospital. Yamaguchi Medical Journal 2020; 69(2): 75 doi: 10.2342/ymj.69.75
|
| 8 |
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, Hitoshi Yoshiji. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. Journal of Clinical Medicine 2022; 11(6): 1571 doi: 10.3390/jcm11061571
|
| 9 |
Yudai Fujiwara, Kazuyuki Suzuki, Kenji Yusa, Makoto Eizuka, Manami Miura, Yuki Watanabe, Hiroshi Takahashi, Yasuhiro Takikawa. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy. Internal Medicine 2021; 60(7): 1027 doi: 10.2169/internalmedicine.5793-20
|
| 10 |
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina 2022; 58(9): 1276 doi: 10.3390/medicina58091276
|
| 11 |
Yoshihito Uchida, Shohei Tsuji, Hayato Uemura, Jun‐ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Masamitsu Nakao, Mie Inao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis. Hepatology Research 2020; 50(11): 1264 doi: 10.1111/hepr.13564
|
| 12 |
Tanya Lew, Papanin Putsathit, Kyung Mok Sohn, Yuan Wu, Kentaro Ouchi, Yoshikazu Ishii, Kazuhiro Tateda, Thomas V. Riley, Deirdre A. Collins. Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015. Antimicrobial Agents and Chemotherapy 2020; 64(7) doi: 10.1128/AAC.00296-20
|